Eledon Pharmaceuticals, Inc. (2TK.F)

2,3800 +0,0600 (+2,59%) Börsenschluss: 08:31AM CEST

Eledon Pharmaceuticals, Inc.

19900 MacArthur Boulevard
Suite 550
Irvine, CA 92612
United States
(949) 238-8090
https://eledon.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 20

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. David-Alexandre C. Gros M.D., Ph.D.	CEO & Non Independent Director	808,24k	N/A	1972
Dr. Steven N. Perrin Ph.D.	President, Chief Scientific Officer & Non Independent Director	591,61k	N/A	1966
Mr. Paul Sean Little	Chief Financial Officer	580,32k	N/A	1965
Mr. John Herberger	Vice President of Technical Operations	N/A	N/A	N/A
Mr. Bryan E. Smith J.D.	General Counsel, Corporate Secretary & Chief Compliance Officer	351,84k	N/A	1980
Dr. David Hovland Ph.D.	Chief Regulatory Officer	N/A	N/A	N/A
Dr. Eliezer Katz F.A.C.S., FACS, M.D.	Chief Medical Officer	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for kidney transplantation, xenotransplantation, and liver transplantation. The company has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

Corporate Governance

Eledon Pharmaceuticals, Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.